The stock of Cognition Therapeutics Inc (NASDAQ: CGTX) has increased by 32.64 when compared to last closing price of 0.24. Despite this, the company has experienced a 6.77% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-28 that PURCHASE, N.Y., May 28, 2025 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its tenth Conversations video podcast episode: “Studying the Patient/Caregiver Lived Experience in Dementia with Lewy Bodies.”
Is It Worth Investing in Cognition Therapeutics Inc (NASDAQ: CGTX) Right Now?
The 36-month beta value for CGTX is also noteworthy at 0.74. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CGTX is 50.25M, and at present, short sellers hold a 2.68% of that float. The average trading volume of CGTX on June 03, 2025 was 761.14K shares.
CGTX’s Market Performance
CGTX stock saw a decrease of 6.77% in the past week, with a monthly decline of -29.11% and a quarterly a decrease of -26.35%. The volatility ratio for the week is 15.80%, and the volatility levels for the last 30 days are 9.23% for Cognition Therapeutics Inc (CGTX). The simple moving average for the past 20 days is -0.39% for CGTX’s stock, with a -38.18% simple moving average for the past 200 days.
Analysts’ Opinion of CGTX
Many brokerage firms have already submitted their reports for CGTX stocks, with B. Riley Securities repeating the rating for CGTX by listing it as a “Buy.” The predicted price for CGTX in the upcoming period, according to B. Riley Securities is $1.50 based on the research report published on December 19, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to CGTX, setting the target price at $22 in the report published on November 03rd of the previous year.
CGTX Trading at -13.81% from the 50-Day Moving Average
After a stumble in the market that brought CGTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.50% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGTX starting from Ricciardi Lisa, who purchase 38,851 shares at the price of $0.77 back on Jan 31 ’25. After this action, Ricciardi Lisa now owns 38,851 shares of Cognition Therapeutics Inc, valued at $30,001 using the latest closing price.
Stock Fundamentals for CGTX
The total capital return value is set at -4.27. Equity return is now at value -161.93, with -106.81 for asset returns.
Based on Cognition Therapeutics Inc (CGTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -65.63. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -5363.9.
Currently, EBITDA for the company is -33.68 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.09.
Conclusion
In summary, Cognition Therapeutics Inc (CGTX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
